These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19346026)

  • 1. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
    Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A
    Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed-induced typhlitis in non-small cell lung cancer.
    Shvartsbeyn M; Edelman MJ
    J Thorac Oncol; 2008 Oct; 3(10):1188-90. PubMed ID: 18827618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed in first-line treatment of non-small cell lung cancer.
    Esteban E; Casillas M; Cassinello A
    Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
    Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
    Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
    Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
    Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
    Barlési F; Tummino C; Tasei AM; Astoul P
    Lung Cancer; 2006 Dec; 54(3):423-5. PubMed ID: 17049669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed.
    Stavroulopoulos A; Nakopoulou L; Xydakis AM; Aresti V; Nikolakopoulou A; Klouvas G
    Ren Fail; 2010; 32(8):1000-4. PubMed ID: 20722569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed-induced pneumonitis: a case report.
    Loriot Y; Ferte C; Gomez-Roca C; Moldovan C; Bahleda R; Wislez M; Cadranel J; Soria JC
    Clin Lung Cancer; 2009 Sep; 10(5):364-6. PubMed ID: 19808196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
    Maione P; Rossi A; Di Maio M; Gridelli C
    Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed and maintenance therapy for non-small cell lung cancer.
    Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
    [No Abstract]   [Full Text] [Related]  

  • 14. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy for advanced stage non-small cell lung cancer.
    Fathi AT; Brahmer JR
    Semin Thorac Cardiovasc Surg; 2008; 20(3):210-6. PubMed ID: 19038730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
    Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
    Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed-induced lung toxicity: a case report.
    Breuer S; Nechushtan H
    Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):76-7. PubMed ID: 21924594
    [No Abstract]   [Full Text] [Related]  

  • 18. [Non-small cell lung cancer - from treatment of relapse to treatments for relapses].
    Souquet PJ
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S108-13. PubMed ID: 18235402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Painful generalized erythematous patches: a severe and unusual cutaneous reaction to pemetrexed.
    Vitiello M; Romanelli P; Kerdel FA
    J Am Acad Dermatol; 2011 Jul; 65(1):243-4. PubMed ID: 21679840
    [No Abstract]   [Full Text] [Related]  

  • 20. [Second-line treatment of advanced non-small-cell lung cancer: role of pemetrexed].
    Pérol M
    Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S14-7. PubMed ID: 16273004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.